1. Home
  2. HIO vs CCCC Comparison

HIO vs CCCC Comparison

Compare HIO & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western Asset High Income Opportunity Fund Inc.

HIO

Western Asset High Income Opportunity Fund Inc.

SELL

Current Price

$3.22

Market Cap

311.9M

Sector

Finance

ML Signal

SELL

Logo C4 Therapeutics Inc.

CCCC

C4 Therapeutics Inc.

SELL

Current Price

$2.65

Market Cap

350.6M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
HIO
CCCC
Founded
1993
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
311.9M
350.6M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
HIO
CCCC
Price
$3.22
$2.65
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
★ $12.86
AVG Volume (30 Days)
646.3K
★ 2.1M
Earning Date
01-01-0001
11-05-2026
Dividend Yield
★ 10.33%
N/A
EPS Growth
N/A
★ 16.45
EPS
★ N/A
N/A
Revenue
N/A
★ $35,947,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 1.02
52 Week Low
$3.24
$1.69
52 Week High
$3.89
$5.17

Technical Indicators

Market Signals
Indicator
HIO
CCCC
Relative Strength Index (RSI) 31.74 33.80
Support Level N/A $2.52
Resistance Level $3.69 $3.91
Average True Range (ATR) 0.04 0.21
MACD 0.00 -0.01
Stochastic Oscillator 8.00 0.68

Price Performance

Historical Comparison
HIO
CCCC

About HIO Western Asset High Income Opportunity Fund Inc.

Western Asset High Income Oppor Fd Inc is a diversified closed-end management investment company. The company's primary objective is to seek high current income and the secondary objective is capital appreciation. It invests a majority of its net assets in high-yield corporate debt securities and the rest in common stock equivalents, including options, warrants, and rights. The company invests in securities of companies from various sectors such as energy, technology, utilities, industrials, communications, finance, and capital goods among others.

About CCCC C4 Therapeutics Inc.

C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.

Share on Social Networks: